RSV Disease in the Elderly
NCT00246480 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1401
Last updated 2019-02-04
Summary
Respiratory syncytial virus (RSV) causes sickness and deaths in older people every winter. This study will investigate how aging affects the body's immune response (body's response to disease) to RSV. About 2000 people, age 21 and older, who reside in the upstate NY area, will be recruited. Two groups of subjects will be studied. The 1st group of volunteers will be recruited prior to the start of RSV season in year 1 of the study. These volunteers will include healthy people and people with various medical conditions. The 2nd group of volunteers will be patients admitted to Rochester General Hospital for acute respiratory illness. Procedures will include drawing blood from a vein in the arm (2 tablespoons), collecting nasal swabs, and collecting sputum. Volunteers may participate in study related procedures for up to 3 years.
Conditions
- Respiratory Infections, Acute
- Respiratory Syncytial Virus
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Min Age
- 21 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-10-03
- Primary Completion
- 2008-05-28
- Completion
- 2008-05-28
Countries
- United States
Study Locations
More Related Trials
-
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
NCT04908683 ·Status: COMPLETED ·Phase: PHASE3
-
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
NCT01805921 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
NCT05842967 ·Status: COMPLETED ·Phase: PHASE3
-
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
NCT02266628 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT02508194 ·Status: TERMINATED ·Phase: PHASE2
-
The Development of a Human Model of Respiratory Syncytial Virus Infection
NCT01349543 ·Status: COMPLETED ·Phase: NA
-
A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease
NCT06077968 ·Status: ACTIVE_NOT_RECRUITING
-
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
NCT06077149 ·Status: COMPLETED ·Phase: PHASE4
-
Novel Mucosal Correlates Of RSV Protection In Older Adults
NCT06274619 ·Status: COMPLETED ·Phase: NA
-
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
NCT03529773 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
NCT06251024 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
NCT04227210 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults
NCT04453202 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
NCT02115815 ·Status: COMPLETED ·Phase: PHASE1
-
RSV Observational Study 2
NCT01922648 ·Status: COMPLETED
-
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
NCT06287450 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
NCT05590403 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
NCT02593071 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
NCT06237296 ·Status: COMPLETED ·Phase: PHASE1